Colchicine
- PMID: 28613754
- Bookshelf ID: NBK431102
Colchicine
Excerpt
Colchicine is FDA-approved for gout prevention, treatment of acute gouty flares, and familial Mediterranean fever. Off-label applications include hepatic cirrhosis, primary biliary cirrhosis, and pseudogout. The primary mechanism of action involves anti-inflammatory effects, which are central to managing these conditions. Understanding the pharmacodynamics, dosing, adverse event profile, and toxicity is essential for optimizing patient outcomes.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
References
-
- Thompson PL, Nidorf SM. Colchicine: an affordable anti-inflammatory agent for atherosclerosis. Curr Opin Lipidol. 2018 Dec;29(6):467-473. - PubMed
-
- Vaidya K, Martínez G, Patel S. The Role of Colchicine in Acute Coronary Syndromes. Clin Ther. 2019 Jan;41(1):11-20. - PubMed
-
- Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, Ozdogan H, Abu I, Gattorno M, Hawkins PN, Yuce S, Kallinich T, Bilginer Y, Kastner D, Carmona L. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016 Apr;75(4):644-51. - PubMed
-
- Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, Brucato A, Gueret P, Klingel K, Lionis C, Maisch B, Mayosi B, Pavie A, Ristic AD, Sabaté Tenas M, Seferovic P, Swedberg K, Tomkowski W, ESC Scientific Document Group 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015 Nov 07;36(42):2921-2964. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources